Anifrolumab Subsidized under s100 PBS for SLE Patients
Key Questions
What is the significance of the PBS s100 subsidy approval for anifrolumab in SLE patients?
The approval expands subsidized access to anifrolumab as the second major biologic for SLE treatment in Australia. It is supported by efficacy data stratified by type I IFN gene signature and advocacy from ASCIA for future subcutaneous formulations.
What do real-world studies show about anifrolumab's impact on SLE disease activity?
The ASTER study demonstrates SLEDAI improvements mainly in skin, joint, and hematologic domains. Four-year data further confirm sustained hematologic and serologic benefits, reinforcing treat-to-target approaches in clinical practice.
How does anifrolumab relate to steroid-sparing strategies in SLE management?
Recent data on the burden of steroid use in systemic lupus erythematosus highlight the need for alternatives that reduce long-term steroid exposure. Anifrolumab supports these strategies by providing effective disease control as a biologic therapy.
PBS s100 subsidy approval for anifrolumab in SLE patients—second major biologic access expansion. Efficacy stratified by type I IFN gene signature; ASCIA advocacy notes Saphnelo subcutaneous/autoinjector formulation (2026). Real-world ASTER study shows SLEDAI improvement mainly in skin/joint/hematologic domains. New four-year data confirm sustained hematologic/serologic improvement, reinforcing treat-to-target approaches. A recent article on steroid burden further underscores the need for steroid-sparing strategies, aligning with anifrolumab's role.